An Innovation Leader in Immuno-Dermatology
Latest News
- Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline 12 February 2024 - Alys Pharmaceuticals, Inc. (“Alys”), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
Events
There are currently no upcoming events
